JP2021512608A5 - - Google Patents
Info
- Publication number
- JP2021512608A5 JP2021512608A5 JP2020542161A JP2020542161A JP2021512608A5 JP 2021512608 A5 JP2021512608 A5 JP 2021512608A5 JP 2020542161 A JP2020542161 A JP 2020542161A JP 2020542161 A JP2020542161 A JP 2020542161A JP 2021512608 A5 JP2021512608 A5 JP 2021512608A5
- Authority
- JP
- Japan
- Prior art keywords
- extracellular vesicle
- item
- macrophage
- macrophages
- phenotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024154757A JP2024166292A (ja) | 2018-02-12 | 2024-09-09 | マクロファージ分極のための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629563P | 2018-02-12 | 2018-02-12 | |
| US62/629,563 | 2018-02-12 | ||
| PCT/US2019/017731 WO2019157535A1 (en) | 2018-02-12 | 2019-02-12 | Methods and compositions for macrophage polarization |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154757A Division JP2024166292A (ja) | 2018-02-12 | 2024-09-09 | マクロファージ分極のための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512608A JP2021512608A (ja) | 2021-05-20 |
| JP2021512608A5 true JP2021512608A5 (enExample) | 2022-02-22 |
Family
ID=65729420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542161A Ceased JP2021512608A (ja) | 2018-02-12 | 2019-02-12 | マクロファージ分極のための方法及び組成物 |
| JP2024154757A Pending JP2024166292A (ja) | 2018-02-12 | 2024-09-09 | マクロファージ分極のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024154757A Pending JP2024166292A (ja) | 2018-02-12 | 2024-09-09 | マクロファージ分極のための方法及び組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11512315B2 (enExample) |
| EP (2) | EP3752615B1 (enExample) |
| JP (2) | JP2021512608A (enExample) |
| KR (1) | KR20200120624A (enExample) |
| CN (2) | CN119614501A (enExample) |
| AU (1) | AU2019218991A1 (enExample) |
| BR (1) | BR112020016228A2 (enExample) |
| CA (1) | CA3088009A1 (enExample) |
| CL (1) | CL2020002053A1 (enExample) |
| CO (1) | CO2020009694A2 (enExample) |
| EA (1) | EA202091486A1 (enExample) |
| IL (1) | IL276409A (enExample) |
| MX (1) | MX2020008103A (enExample) |
| PH (1) | PH12020551195A1 (enExample) |
| SG (1) | SG11202006021SA (enExample) |
| TW (1) | TW202003846A (enExample) |
| WO (1) | WO2019157535A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019218991A1 (en) | 2018-02-12 | 2020-07-09 | Lonza Sales Ag | Methods and compositions for macrophage polarization |
| AU2019242912B2 (en) | 2018-03-28 | 2025-07-17 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in DNA isolated from exosomes |
| US12312584B2 (en) | 2018-10-02 | 2025-05-27 | Exosome Therapeutics, Inc. | cGMP exosome loaded therapeutics for treating sickle cell disease |
| WO2020106772A1 (en) * | 2018-11-19 | 2020-05-28 | Exosome Therapeutics, Inc. | Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency |
| KR20220078565A (ko) * | 2019-08-14 | 2022-06-10 | 코디악 바이오사이언시즈, 인크. | 분자에 연결된 세포외 소포 및 이의 용도 |
| WO2021030769A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with nras antisense oligonucleotides |
| JP2022544289A (ja) * | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ， インコーポレイテッド | Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物 |
| CN114641570A (zh) * | 2019-08-14 | 2022-06-17 | 科迪亚克生物科学公司 | 具有靶向kras的反义寡核苷酸的细胞外囊泡 |
| BR112022002690A2 (pt) * | 2019-08-14 | 2022-08-23 | Codiak Biosciences Inc | Construtos de vesícula-aso extracelular tendo como alvo cebp/beta |
| JP2022549328A (ja) * | 2019-09-25 | 2022-11-24 | コディアック バイオサイエンシーズ， インコーポレイテッド | 細胞外小胞組成物 |
| CN115297850A (zh) * | 2019-12-05 | 2022-11-04 | 得克萨斯州大学系统董事会 | 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗 |
| CN115768877A (zh) | 2020-05-11 | 2023-03-07 | 斯特姆生物公司 | 与巨核细胞来源的细胞外囊泡相关的组合物和方法 |
| WO2021237100A1 (en) * | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| CN111748523B (zh) * | 2020-07-17 | 2022-11-22 | 南通大学 | 一种免疫调节小胞外囊泡的制备方法及其用途 |
| WO2022076596A1 (en) * | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| US20230405118A1 (en) * | 2020-10-30 | 2023-12-21 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Stat-activated macrophages, compositions, and uses thereof |
| AU2022216260A1 (en) * | 2021-02-03 | 2023-08-17 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating disease associated with dux4 overexpression |
| US12521449B2 (en) | 2021-04-26 | 2026-01-13 | Strm.Bio Incorporated | Compositions and methods related to megakaryocyte-derived extracellular vesicles for Fanconi Anemia |
| CN113262305B (zh) * | 2021-05-27 | 2022-03-25 | 浙江大学 | Coro1a基因作为靶点在制备抗肿瘤药物中的应用 |
| EP4365175A4 (en) | 2021-07-02 | 2025-06-25 | Spark Biopharma, Inc. | Novel benzopyran derivative and use thereof |
| CN113521252B (zh) * | 2021-07-29 | 2022-12-20 | 南开大学 | Tnfsf15蛋白作为巨噬细胞免疫增强剂的用途及其活化方法 |
| US20240392293A1 (en) * | 2021-09-02 | 2024-11-28 | Molecular Axiom, Llc | Compositions and methods for modulating kras expression |
| CN118434857A (zh) * | 2021-10-21 | 2024-08-02 | 纳诺瑟拉生物科学股份有限公司 | 用于沉默kras的组合物以及方法 |
| CN114058621B (zh) * | 2021-12-03 | 2023-06-16 | 温州医科大学 | 一种lncRNA基因修饰细胞分泌的外泌体及应用 |
| CN114209814B (zh) * | 2021-12-15 | 2024-02-23 | 南开大学 | Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途 |
| CN114561347A (zh) * | 2022-02-25 | 2022-05-31 | 和携科技有限公司 | 一种脂肪间充质干细胞的培养基和培养方法 |
| CN115948496A (zh) * | 2022-04-15 | 2023-04-11 | 健艾仕生物医药科技(杭州)有限公司 | 一种巨噬细胞极化过程高通量检测的方法及应用 |
| CN115137708B (zh) * | 2022-06-24 | 2023-05-16 | 重庆医科大学 | 装载yap1核酸序列的肝纤维化靶向纳米颗粒及其制备方法和应用 |
| EP4554984A1 (en) * | 2022-07-13 | 2025-05-21 | Navidea Biopharmaceuticals, Inc. | Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells |
| CN115261410A (zh) * | 2022-07-20 | 2022-11-01 | 中山大学 | 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用 |
| EP4599252A2 (en) * | 2022-08-26 | 2025-08-13 | Georgia State University Research Foundation, Inc. | Treating chronic inflammation and cancer by macrophage polarization |
| CN115814108B (zh) * | 2022-12-27 | 2025-04-25 | 华中科技大学 | 一种用于个性化肿瘤治疗的工程化巨噬细胞载药微颗粒制剂及其制备方法 |
| CN116370647B (zh) * | 2023-04-11 | 2025-07-11 | 吉林大学 | 一种用于胰腺癌免疫治疗的工程化外泌体及制备方法 |
| CN119215144B (zh) * | 2023-09-08 | 2025-08-08 | 首都医科大学附属北京朝阳医院 | Lrg1在制备促进巨噬细胞向m1型分化的药物中的应用和巨噬细胞激活剂 |
| KR102635831B1 (ko) * | 2023-11-01 | 2024-02-13 | 강원대학교 산학협력단 | Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517644B1 (en) * | 1991-08-23 | 2009-04-14 | Larry J. Smith | Method and compositions for cellular reprogramming |
| US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| BR0111798A (pt) * | 2000-06-19 | 2006-12-26 | Halliburton Energy Serv Inc | aparelho e métodos para aplicação de vsp de retardo de tempo para monitorar um reservatório |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| US20040115634A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Modulation of stat 6 expression |
| DE102004026309A1 (de) * | 2004-05-26 | 2005-12-29 | Haarlems Allergenen Laboratorium B.V. | Pharamzeutische Zusammensetzung zur Behandlung allergischer Erkrankungen, pathologischer Atemswegsveränderungen und von Krebs durch Modulation der Genexpression des Stat6 |
| DE102006050655A1 (de) * | 2006-10-24 | 2008-04-30 | Halmon Beheer B.V. | Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| ES2628144T3 (es) * | 2009-04-03 | 2017-08-01 | Dicerna Pharmaceuticals, Inc. | Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico |
| WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US20150301058A1 (en) * | 2012-11-26 | 2015-10-22 | Caris Science, Inc. | Biomarker compositions and methods |
| US20160243192A1 (en) * | 2013-10-17 | 2016-08-25 | Children's Hospital Los Angeles | Antibody dependent exosome therapy |
| US20160346334A1 (en) * | 2014-02-05 | 2016-12-01 | Stc.Unm | Exosomes as a therapeutic for cancer |
| ES2727154T3 (es) * | 2014-10-24 | 2019-10-14 | Astrazeneca Ab | Combinación |
| IL256175B2 (en) * | 2015-06-10 | 2024-10-01 | Univ Texas | Using exosomes to treat the disease |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| HK1255699A1 (zh) * | 2015-09-24 | 2019-08-23 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| SG10202008883SA (en) * | 2016-03-15 | 2020-10-29 | Codiak Biosciences Inc | Therapeutic membrane vesicles |
| US12622876B2 (en) | 2016-08-22 | 2026-05-12 | Lonza Sales Ag | Methods of suppressing delivery of exosomes to liver and spleen |
| MX2020001790A (es) | 2017-08-25 | 2020-07-22 | Codiak Biosciences Inc | Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana. |
| AU2019218991A1 (en) | 2018-02-12 | 2020-07-09 | Lonza Sales Ag | Methods and compositions for macrophage polarization |
| KR20220078565A (ko) * | 2019-08-14 | 2022-06-10 | 코디악 바이오사이언시즈, 인크. | 분자에 연결된 세포외 소포 및 이의 용도 |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| JP2025509183A (ja) * | 2022-03-04 | 2025-04-11 | アイ－エムエービー バイオファーマ ユーエス リミテッド | がんの処置のためのｋｒａｓ阻害剤を含む併用療法 |
-
2019
- 2019-02-12 AU AU2019218991A patent/AU2019218991A1/en not_active Abandoned
- 2019-02-12 US US16/969,511 patent/US11512315B2/en active Active
- 2019-02-12 EP EP19710511.7A patent/EP3752615B1/en active Active
- 2019-02-12 EP EP25198027.2A patent/EP4663245A3/en active Pending
- 2019-02-12 EA EA202091486A patent/EA202091486A1/ru unknown
- 2019-02-12 MX MX2020008103A patent/MX2020008103A/es unknown
- 2019-02-12 CN CN202411511570.7A patent/CN119614501A/zh active Pending
- 2019-02-12 JP JP2020542161A patent/JP2021512608A/ja not_active Ceased
- 2019-02-12 KR KR1020207022341A patent/KR20200120624A/ko not_active Ceased
- 2019-02-12 CA CA3088009A patent/CA3088009A1/en active Pending
- 2019-02-12 SG SG11202006021SA patent/SG11202006021SA/en unknown
- 2019-02-12 BR BR112020016228-0A patent/BR112020016228A2/pt not_active IP Right Cessation
- 2019-02-12 WO PCT/US2019/017731 patent/WO2019157535A1/en not_active Ceased
- 2019-02-12 TW TW108104676A patent/TW202003846A/zh unknown
- 2019-02-12 CN CN201980011011.0A patent/CN111918967B/zh active Active
-
2020
- 2020-07-30 IL IL276409A patent/IL276409A/en unknown
- 2020-08-05 CO CONC2020/0009694A patent/CO2020009694A2/es unknown
- 2020-08-06 PH PH12020551195A patent/PH12020551195A1/en unknown
- 2020-08-07 CL CL2020002053A patent/CL2020002053A1/es unknown
-
2022
- 2022-11-04 US US18/052,785 patent/US12570978B2/en active Active
-
2024
- 2024-09-09 JP JP2024154757A patent/JP2024166292A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance | |
| Kieran et al. | Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma | |
| Jarosz-Biej et al. | M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma | |
| US20230365971A1 (en) | Methods and compositions for macrophage polarization | |
| US12383575B2 (en) | Polyinosinic—polycytidylic acid compositions | |
| CN104427992B (zh) | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 | |
| JP2021529753A5 (enExample) | ||
| JP2002517434A (ja) | 免疫系を刺激する方法 | |
| US11680266B2 (en) | Endomucin inhibitor as an anti-angiogenic agent | |
| CN116829583A (zh) | 延长健康期限和治疗年龄相关疾病的方法 | |
| Liu et al. | Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus | |
| JP2024020338A (ja) | 白斑を処置するための方法及び組成物 | |
| EP3942097A1 (en) | Chmp2a as a regulator of natural killer cell-mediated activity | |
| JP2019534322A (ja) | Ｔｉｍ−３の上昇を処置する方法 | |
| EP4739707A1 (en) | Il-1ra blockers for treatment and prevention of sepsis | |
| TH2001004404A (th) | วิธีการและองค์ประกอบสำหรับการโพลาไรเซชันมาโครฟาจ | |
| KR102561720B1 (ko) | 종양에 대한 직접적인 억제 효과를 갖는 인터페론의 결정 방법 및 그 용도 | |
| WO2023080157A1 (ja) | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）の治療又は予防剤、並びに、ｈａｍの治療有効性判定方法、活動性評価方法又は診断方法 | |
| WO2022109022A1 (en) | Rna-targeting splicing modifiers for treatment of mda5-associated conditions and diseases | |
| Bilicki et al. | Glioblastoma-actual knowledge and future perspectives | |
| WO2017085566A1 (en) | Methods and compositions for increase/induction of immune responses | |
| CN117460526A (zh) | 用于治疗癌症的分枝杆菌免疫疗法 | |
| WO2026107366A1 (en) | Targeting il1r1, meox1, and maff for treatment of inflammatory bowel disease | |
| WO2026102329A1 (en) | Methods and compositions for predicting response to oncolytic virotherapy | |
| HK40121253A (zh) | 适配体、其药物组合物以及预防或治疗bcma相关疾病或病症的方法 |